Nyxoah (NYXH) Set to Announce Earnings on Wednesday

Nyxoah (NASDAQ:NYXH) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.01). Nyxoah had a negative net margin of 908.32% and a negative return on equity of 42.00%. The company had revenue of $0.83 million during the quarter, compared to analyst estimates of $1.93 million. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nyxoah Trading Down 1.2 %

Shares of NASDAQ:NYXH opened at $9.44 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.16 and a current ratio of 5.47. Nyxoah has a 12-month low of $4.00 and a 12-month high of $20.00. The business has a 50 day moving average of $8.85 and a 200-day moving average of $8.81.

Wall Street Analysts Forecast Growth

NYXH has been the topic of a number of recent research reports. HC Wainwright lowered their price target on shares of Nyxoah from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, October 11th. Cantor Fitzgerald dropped their price target on Nyxoah from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Finally, Oppenheimer decreased their target price on shares of Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nyxoah has an average rating of “Buy” and an average price target of $17.00.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.